Cantor Fitzgerald’s LumiraDx Limited Warrant LMDXW Stock Holding History

Cantor Fitzgerald’s Portfolio LMDXW Stock Details LMDXW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-12,050	Closed	-$17K	–	463
2021 Q4	$17K	Buy	+12,050	New	+$19.4K	﹤0.01%	383

Other funds holding LMDXW

CVS Health Woonsocket, Rhode Island $212M AUM 19.39% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCC

Spring Creek Capital Wichita, Kansas $2.53B AUM 19.59% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

MCM

Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

Capstone Investment Advisors New York $57.4B AUM 26.91% 1-Year Est. Return

Cantor Fitzgerald's LMDXW Position: Q1 2022 in Review

Cantor Fitzgerald sold out of LumiraDx Limited Warrant (LMDXW) in Q1 2022, closing a stake of 12,050 shares — an estimated $17K sold.

Cantor Fitzgerald first reported a position in LMDXW in Q4 2021 and held it in 1 quarter. The position peaked at $17K in Q4 2021. 20 funds tracked by Wall St. Rank hold LMDXW as of Q1 2022.

Cantor Fitzgerald reported no remaining LumiraDx Limited Warrant position as of Q1 2022 after selling out during the quarter.
Cantor Fitzgerald sold 12,050 LumiraDx Limited Warrant shares in Q1 2022, an estimated $17K.
Cantor Fitzgerald first reported a position in LumiraDx Limited Warrant in Q4 2021 and held it in 1 quarter.
Cantor Fitzgerald's LumiraDx Limited Warrant position peaked at $17K in Q4 2021.
20 funds tracked by Wall St. Rank held LumiraDx Limited Warrant as of Q1 2022.

Based on Cantor Fitzgerald's 13F filing for Q1 2022, filed 16 May 2022.